Document Detail


Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia.
MedLine Citation:
PMID:  22676879     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To develop a mathematical model to project the potential impact of hepatitis C virus (HCV) treatment on HCV infection prevalence among people who inject drugs (PWID).
DESIGN AND SETTING: An existing model of HCV transmission among PWID was parameterised using data from Victoria, Australia, including specific parameter estimates of the number of people who are currently active injecting drug users, average duration of injecting, chronic HCV infection prevalence among PWID, annual mortality, and annual HCV treatment rate. We also explored the impact of prevalence uncertainty, program scale-up, and new treatments.
MAIN OUTCOME MEASURE: Prevalence of chronic HCV infection among people who are currently active injecting drug users.
RESULTS: With annual treatment rates of 13, 17, or 25 per 1000 PWID, the model predicts relative prevalence reductions of 20%, 30%, and 50%, respectively, within 30 years. If new treatments giving higher sustained viral response rates are available in 5 years, estimated impact is increased by 21%–23% at 15 years, and 17%–38% at 30 years, depending on treatment rates.
CONCLUSIONS: This model suggests that modest rates of current HCV treatment among PWID in Victoria, Australia could halve HCV infection prevalence among PWID in 30 years. This finding suggests that interventions aimed at increasing access to HCV treatment in community clinics will benefit individual PWID and reduce HCV infection prevalence.
Authors:
Margaret E Hellard; Rebecca Jenkinson; Peter Higgs; Mark A Stoové; Rachel Sacks-Davis; Judy Gold; Matthew Hickman; Peter Vickerman; Natasha K Martin
Related Documents :
22428029 - Downregulation of the au-rich rna-binding protein zfp36 in chronic hbv patients: implic...
22807539 - High prevalence of hepatitis b and syphilis co-infections among hiv patients initiating...
22327459 - Epidemiology of acute osteoarticular sepsis in a setting with a high prevalence of pedi...
22859499 - Incidence of acute hepatitis c virus infection among men who have sex with men with and...
15166279 - Diagnosis of aspergillus peritonitis in a renal dialysis patient by pcr and galactomann...
22917869 - Second line protease inhibitor (pi/r) based antiretroviral therapy (art) after non-nucl...
15018849 - Detection of bk virus and jc virus dna in urine samples from immunocompromised (hiv-inf...
23289189 - Evaluation of human immunodeficiency virus-1/2 antigen/antibody immunochromatographic a...
19853339 - Routine checks for hiv in children attending primary health care facilities in south af...
Publication Detail:
Type:  Evaluation Studies; Journal Article    
Journal Detail:
Title:  The Medical journal of Australia     Volume:  196     ISSN:  1326-5377     ISO Abbreviation:  Med. J. Aust.     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-06-08     Completed Date:  2012-08-16     Revised Date:  2014-03-14    
Medline Journal Info:
Nlm Unique ID:  0400714     Medline TA:  Med J Aust     Country:  Australia    
Other Details:
Languages:  eng     Pagination:  638-41     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antiviral Agents / therapeutic use*
Drug Therapy, Combination
Drug Users*
Hepatitis C, Chronic / epidemiology,  prevention & control*,  transmission
Humans
Interferon-alpha / therapeutic use*
Models, Biological*
Polyethylene Glycols / therapeutic use*
Prevalence
Recombinant Proteins / therapeutic use
Ribavirin / therapeutic use*
Substance Abuse, Intravenous / complications*
Victoria / epidemiology
Grant Support
ID/Acronym/Agency:
G0701627//Medical Research Council; G1000021//Medical Research Council; PDF-2011-04-049//Department of Health; RP-DG-0610-10055//Department of Health
Chemical
Reg. No./Substance:
0/Antiviral Agents; 0/Interferon-alpha; 0/Polyethylene Glycols; 0/Recombinant Proteins; 0/peginterferon alfa-2a; 49717AWG6K/Ribavirin
Comments/Corrections
Comment In:
Med J Aust. 2012 Jun 4;196(10):614   [PMID:  22676864 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatitis C treatment outcomes in Australian clinics.
Next Document:  Pharmacoepidemiology of testosterone prescribing in Australia, 1992-2010.